Active Ingredient(s): Duvelisib
FDA Approved: * September 24, 2018
Pharm Company: * VERASTEM INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Copiktra Overview

Duvelisib (INN,[1] previously known as IPI-145) is a dual inhibitor of PI3Kδ and PI3Kγ,[2] in development as a treatment for hematologic malignancies as well as a broad range of inflammatory conditions.[3] The phosphoinositide 3-kinases are involved in cell proliferation and differentiation and have significant potential in hematology fields and inflammatory disease treatments.[2] Ibrutinib and acalabrutinib are other i...

Read more Copiktra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Copiktra Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 15mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Duvelisib or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 October 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA